This move is archived. Current quotes and coverage live on the stock page.
Follow LABS
Medipharm Labs Corp faces a significant downturn as its stock drops 6.67% in a single trading session.
In a disappointing turn for investors, Medipharm Labs Corp (LABS.TO) saw its stock price fall by 6.67% in the latest trading session, closing at CA$0.07. This decline raises concerns about the company's current performance and future prospects.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$32.04M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.93
Analyst Price Targets
Based on analyst covering LABS · as of Sep 17, 2026
Wall Street analysts forecast LABS stock price to rise 42.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+42.9% Upside
Current Price
C$0.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
61.9%
Annualized
90-Day Vol
72.1%
Annualized
Trend (90d)
+29.0%
Annualized drift
90d Mean
C$0.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.08 | C$0.06 – C$0.10 |
| 60 trading days | C$0.08 | C$0.06 – C$0.11 |
| 90 trading days | C$0.08 | C$0.06 – C$0.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor Medipharm Labs Corp as it navigates a challenging market environment, especially given its recent financial performance and the competitive landscape in the cannabis sector.
Medipharm Labs Corp stock drops 6.67%
The market cap of Medipharm Labs Corp now stands at approximately CA$29.74 million, reflecting investor sentiment amid the stock's recent performance.
Bull case
Despite the current downturn, Medipharm Labs has potential for growth. The company has reported positive adjusted EBITDA in previous quarters and is strategically positioned to take advantage of U.S. pharmaceutical demand.
Bear case
The recent stock decline highlights ongoing challenges for Medipharm Labs. There’s been a lack of recent positive news, and concerns about profitability remain, as shown by a negative profit margin of -20.21%.
Advertisement
Current Performance Overview
Medipharm Labs Corp's stock performance has been disappointing, with a notable drop of 6.67% in the last trading session. This decline raises questions about the company's ability to maintain investor confidence, especially as it operates in a competitive cannabis market. For more details on its performance, visit the Medipharm Labs stock page.
Financial Health and Market Challenges
With a market cap of CA$29.74 million and a troubling profit margin of -20.21%, Medipharm Labs faces significant financial hurdles. The lack of recent positive news further complicates the outlook for investors. To learn more about its financial metrics, check out the financial details on LABS.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
